Details for New Drug Application (NDA): 208042
✉ Email this page to a colleague
NDA 208042 describes CASSIPA, which is a drug marketed by Teva Pharms Usa and is included in one NDA. Additional details are available on the CASSIPA profile page.
The generic ingredient in CASSIPA is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
The generic ingredient in CASSIPA is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 208042
| Tradename: | CASSIPA |
| Applicant: | Teva Pharms Usa |
| Ingredient: | buprenorphine hydrochloride; naloxone hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FILM;SUBLINGUAL | Strength | EQ 16MG BASE;EQ 4MG BASE | ||||
| Approval Date: | Sep 7, 2018 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
